For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Estrogen Receptor-Beta Variants Are Associated with Increased Risk of Alzheimer’s Disease in Women with Down SyndromeZhao Q.c · Lee J.H.a–c · Pang D.a, g · Temkin A.f · Park N.a · Janicki S.C.a, b, d · Zigman W.B.g · Silverman W.h · Tycko B.a, f · Schupf N.a, c, e
aTaub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, bG.H. Sergievsky Center, and Departments of cEpidemiology, dNeurology, ePsychiatry and fPathology, Columbia University Medical Center, New York, N.Y., gDepartment of Psychology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, N.Y., and hKennedy Krieger Institute and Johns Hopkins University School of Medicine, Baltimore, Md., USA Corresponding Author
Nicole Schupf, PhD
Taub Institute for Research on Alzheimer’s Disease and the Aging Brain
PO Box 16, 630 West 168th Street
New York, NY 10032 (USA)
Tel. +1 212 305 2381, E-Mail firstname.lastname@example.org
Background/Aims: Genetic variants that affect estrogen activity may influence the risk of Alzheimer’s disease (AD). We examined the relation of polymorphisms in the gene for the estrogen receptor-beta (ESR2) to the risk of AD in women with Down syndrome. Methods: Two hundred and forty-nine women with Down syndrome, 31–70 years of age and nondemented at baseline, were followed at 14- to 18-month intervals for 4 years. Women were genotyped for 13 single-nucleotide polymorphisms (SNPs) in the ESR2 gene, and their association with AD incidence was examined. Results: Among postmenopausal women, we found a 2-fold increase in the risk of AD for women carrying 1 or 2 copies of the minor allele at 3 SNPs in introns seven (rs17766755) and six (rs4365213 and rs12435857) and 1 SNP in intron eight (rs4986938) of ESR2. Conclusion: These findings support a role for estrogen and its major brain receptors in modulating susceptibility to AD in women.
© 2011 S. Karger AG, Basel
Experimental and epidemiologic studies have shown that estrogen has neuroprotective effects and that loss of estrogen after menopause may contribute to the cognitive declines associated with Alzheimer’s disease (AD) in women . The neuroprotective mechanisms of estrogen include increases in cholinergic activity [2,3,4], antioxidant activity  and protection against the neurotoxic effects of beta amyloid . Therefore, factors that influence estrogen activity may also influence vulnerability to AD, including an allelic variation in genes within the estrogen biosynthesis and estrogen receptor pathways.
Estrogen exerts many of its effects through the activation of nuclear receptors which are expressed in multiple tissues . In the brain, two estrogen receptors, ER-α and ER-β, encoded by two different genes, ESR1 and ESR2, have been identified and have been found in regions affected by AD, including the hippocampus, basal forebrain and amygdala [8,9]. ER-α and ER-β differ in tissue distribution , with ER-β expression being more predominant than ER-α in the cerebral cortex, hippocampus, anterior olfactory nucleus, dorsal raphe, substantia nigra, midbrain ventral tegmental area and cerebellum [8,11,12], suggesting that ER-β may play a role in memory and the risk for AD . Both ER-α and ER-β appear to have a role in the preservation of cholinergic activity [14,15], and ER-β may mediate the effects of estrogen on hippocampal synaptic plasticity . While a number of studies have examined the relation of AD to variants in ESR1[16,17,18,19,20,21,22], or to genes in the estrogen biosynthetic pathway [23,24,25,26,27], fewer studies have investigated variants in the ESR2 gene and the findings have been less consistent [28,29,30,31,32,33].
Women with Down syndrome (DS) have an early onset of menopause  and a high risk for AD, with onset of dementia 10–20 years earlier than women in the general population [35,36,37]. Brain levels of beta amyloid peptides are high from an early age , likely due, at least in part, to the triplication and overexpression of the gene for amyloid precursor protein located on chromosome 21 . Women with DS with earlier onset of menopause have an earlier onset of AD than women with later onset of menopause , and postmenopausal women with low levels of bioavailable estradiol have both an earlier onset and an increased cumulative incidence of AD than postmenopausal women with high levels of bioavailable estradiol . These findings suggest that reductions in estrogen following menopause may contribute to the cascade of pathological processes leading to AD in this high-risk population. Women with DS carrying the P allele at PvuII in ESR1 have a 2- to 3-fold increased risk of AD compared with those carrying the p allele . In this study, we examined the relationships between SNPs in ESR2 and the risk for AD in a community-based cohort of women with DS.
The initial cohort included a community-based sample of 279 women with DS. Of these 279 women, 252 (90.3%) agreed to provide a blood sample and were genotyped for ESR2. All individuals were 30 years of age or older at study onset and resided in New York, New Jersey, Pennsylvania or Connecticut. In all cases a family member or correspondent provided informed consent (for blood sampling and genotyping included) with participants providing assent. The participation rate was 74.6%. The distribution of the level of intellectual disability and residential placement did not differ between participants and those who did not participate. Recruitment, informed consent and study procedures were approved by the Institutional Review Boards of Columbia University Medical Center and the New York State Institute for Basic Research in Developmental Disabilities.
Assessments were repeated at 14- to 18-month intervals over five cycles of data collection and included evaluations of cognition and functional abilities, behavioral/psychiatric conditions and health status. Cognitive function was evaluated with a test battery designed for use with individuals with DS varying widely in their levels of intellectual functioning, as described previously . Structured interviews were conducted with caregivers to collect information on changes in cognition, function, adaptive behavior and medical status. The past and current medical records of all participants were reviewed.
Menopausal status was ascertained through menstrual charts in medical records, by medical record review, interviews with caregivers and family members and a survey of primary care physicians and gynecologists. The medical records included menstrual charts documenting the date and duration of menses. The correlations between age at menopause ascertained from the different sources were substantial, suggesting that ascertainment of age at menopause was reliable. The correlation between age at menopause ascertained from medical records (including menstrual charts) and from the physician survey was 0.99, the correlation ascertained from medical records and from informant interviews was 0.77 and the correlation ascertained from the physician survey and from informant interviews was 0.80. The mean difference in age at menopause from the different sources ranged from 0.21 years for the difference ascertained from medical charts and the physician survey to 0.38 years for the difference ascertained from medical charts and informant interviews. We used a consensus age at menopause, with greater weight given to that ascertained from medical records, followed by that from the physician survey, then that from informant interviews. In keeping with convention, we classified age at natural menopause as the age at the last menstrual period preceding cessation of menses for 12 months, in the absence of known causes of amenorrhea (e.g. surgery). The median age at menopause was 46.0 years (range 35–52). We were able to ascertain menopausal status for 248 of the 252 participants with ESR2 genotypes (99%). The 4 women with unknown menopausal status were excluded from all analyses. Among the 248 participants with known menopausal status, 146 were postmenopausal, 78 were premenopausal and 21 were perimenopausal. Three women had never menstruated and were excluded, leaving 245 women for analysis.
The classification of dementia status, dementia subtype and age at onset was determined during clinical consensus conferences where information from all available sources was reviewed. Classifications were made blind to ESR2 genotype or information on menopausal status or hormone levels. We classified participants into 2 groups, following the recommendations of the AAMR-IASSID Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Developmental Disability . Participants were classified as nondemented if they were without cognitive or functional decline, or if they showed some cognitive and/or functional decline that was not of significant magnitude to meet dementia criteria (n = 173). Participants were classified as demented if they showed a substantial and consistent decline over the course of follow-up (of a duration of at least one year) and if they had no other medical or psychiatric conditions that might mimic dementia (n = 72). The age at meeting the criteria for dementia was used to estimate the age at the onset of dementia. Only participants with probable or possible AD were included in the analysis. Of the 146 postmenopausal women, 79 were nondemented and 67 had possible or probable AD.
Women who provided a blood sample were karyotyped. We were able to karyotype all but 12 of the 245 participants in this study (95.1%). We found low-level mosaicism (3–15%) in 6 women (2.6%). Their ages were 51, 51, 56, 58, 61 and 68 years. One 43-year-old woman had a high level of mosaicism and mosaic DS was noted in her medical chart. Genomic DNA was extracted from peripheral blood leukocytes, using the FlexiGene DNA kit (Qiagen). Isolation of DNA and genotyping were performed blind to the dementia status of the participant. SNPs reported to be associated with estrogen-related disorders (breast cancer, osteoporosis) and prior studies of AD were selected. Additional SNPs were selected to provide coverage of the gene. We analyzed 13 SNPs in ESR2, 12 of which are within introns of the gene, and the remaining 1 in exon nine (see table 2). SNPs were genotyped using TaqMan® PCR assays (Applied Biosystems) with PCR cycling conditions recommended by the manufacturer, and by PreventionGenetics using proprietary array tape technology. Accuracy of the genotyping (>97%) was verified by including duplicate DNA samples, by comparing the TaqMan and array tape data with the results of restriction digestion polymorphisms/restriction fragment length polymorphisms (RFLPs) for several of the SNPs, and by testing for the Hardy-Weinberg equilibrium.
Apolipoprotein E (APOE) genotyping was carried out by PCR/RFLP analysis using HhaI (CfoI) digestion of an APOE genomic PCR product spanning the polymorphic (cys/arg) sites at codons 112 and 158, followed by acrylamide gel electrophoresis to document the restriction fragment sizes . Participants were classified according to the presence or absence of at least one APOE ε4 allele.
Potential confounders included the presence of an APOE ε4 allele, level of intellectual disability, body mass index (BMI) and ethnicity. Level of intellectual disability was classified as mild-to-moderate (IQ 35–70) or severe-to-profound (IQ <34), based on IQ scores obtained before the onset of AD. BMI was measured at each evaluation; its baseline measure was used in the analysis and was included as a continuous variable. Ethnicity was categorized as white or nonwhite.
Prior to association analysis, we tested all SNPs for the Hardy-Weinberg equilibrium using the Haploview program  and all were found to be in Hardy-Weinberg equilibrium. SNPs were analyzed using a dominant model, in which participants homozygous for the common allele were used as the reference group. In preliminary analyses, the χ2 test (or the Fisher exact test when any cell had <5 subjects) was employed to assess the association between AD and SNP genotypes as well as other possible risk factors for AD including ethnicity, level of intellectual disability and the presence of an APOE ε4 allele. Analysis of variance was used to examine BMI, age and AD status. We used a Cox proportional hazards model to assess the relationship between ESR2 genotypes and age at the onset of AD, adjusting for ethnicity, BMI, level of intellectual disability and the presence of an APOE ε4 allele. The time to event variable was the age at onset for participants who developed AD and the age at the last assessment for participants who remained nondemented throughout the follow-up period. Because a set of 3 contiguous SNPs that span 7.8 kb – rs17766755, rs4365213 and rs12435857 – were significantly associated with AD in postmenopausal women, we performed a haplotype analysis to identify haplotype(s) that may harbor a susceptibility variant(s) as implemented in the PLINK program . For nearly all individuals, we were able to identify the most likely haplotypes from the genotype data with a high degree of certainty (i.e. the posterior probability approaching 1.0 for most cases with the rest exceeding probability >0.7). Subsequently, we used the estimated haplotypes as a ‘super-locus’ (analogous to a microsatellite marker) to perform a Cox proportional hazards model.
The mean age of participants at baseline was 48.9 years (range 31.4–70.1 years) and 88% of the cohort was white. The mean length of follow-up was 4.2 years. Table 1 presents the demographic characteristics of the participants according to AD status. For the total group at baseline, participants with AD were significantly older than nondemented participants (53.9 vs. 46.8 years) and were more likely to have a severe or profound level of intellectual disability (52.8 vs. 35.3%), but did not differ in the distribution of ethnicity, the frequency of the APOE ε4 allele or mean level of BMI. The mean age at onset of AD was 54.7 ± 5.1 years. Among postmenopausal women, participants with AD were significantly older than women who remained nondemented throughout the follow-up period (54.3 vs. 51.7 years), but did not differ from nondemented women in the distribution of level of intellectual disability, ethnicity, the frequency of the APOE ε4 allele or mean BMI.
Table 2 shows the locations and minor allele frequencies of ESR2 SNPs for Hapmap whites at the NCBI SNP website (http://www.ncbi.nlm.nih.gov/projects/SNP) and for our cohort of women with DS. Allele frequencies were similar in women with DS to those observed in women without DS in the general population. Table 3 presents the distributions of ESR2 genotypes and the association between ESR2 SNPs and the hazard ratio (HR) for AD among the total group and among postmenopausal women only. In the total group, women who carried 1 or 2 copies of the A allele at rs17766755 were significantly more likely to develop AD, after adjusting for age, ethnicity, level of intellectual disability, BMI and the presence of an APOE ε4 allele (HR = 1.8, 95% CI 1.0–3.2) (table 3).
Because there were only 5 cases of AD among premenopausal or perimenopausal women, we repeated the analyses, restricting the sample to postmenopausal women. Among postmenopausal women, those who carried at least 1 copy of the T allele at rs4986938 were twice as likely to develop AD as those with the CC genotype. Three contiguous SNPs located approximately 16kb away from rs4986938 were significantly associated with AD. Specifically, carriers of the A allele at rs17766755, the G allele at rs4365213 and the A allele at rs12435857 had a 2.0-fold increase in the hazard rate compared with women carrying no copies of these alleles (HR for rs4986938 (CT or TT) = 1.9, 95% CI 1.01–3.4; HR for rs17766755 (AG or AA) = 2.3, 95% CI 1.2–4.3; HR for rs4365213 (AG or GG) = 1.9, 95% CI 1.03–3.8; HR for rs12435857 (AG or AA) = 2.1, 95% CI 1.1–4.2) (table 3). These results were unchanged when the analysis was repeated among those without an APOE ε4 allele (data not shown).
We first computed the most likely haplotypes for each individual, and then used the haplotypes as a ‘super-locus’ to estimate HRs, controlling for potential confounders. Our haplotype analysis using rs17766755-rs4365213-rs12435857 revealed that the carriers of haplotype AGA had an earlier onset and were twice as likely as noncarriers to develop AD after adjusting for the presence of an APOE ε4 allele level of intellectual disability, ethnicity and BMI (HR = 2.15, 95% CI 1.13–4.11) (fig. 1).
Four SNPs in ESR2 were associated with an increased risk of AD, independent of APOE genotype. Among postmenopausal women, those who carried at least 1 copy of the T allele at rs4986938 were twice as likely to develop AD than those who carried the CC genotype. In addition, approximately 16kb away from rs4986938, a set of 3 contiguous SNPs was significantly associated with AD; these 3 SNPs were located within one haplotype block spanning approximately 7.8 kb (fig. 2). Women with DS who carried the A allele at rs17766755, the G allele at rs4365213 or the A allele at rs12435857 had a 2-fold increased risk of AD, compared with women without these risk alleles. A haplotype-based Cox proportional hazards model continued to support that AGA carriers had a 2-fold risk of developing AD after adjusting for covariates.
The association of these SNPs with an increased risk of AD was seen only among postmenopausal women. Among premenopausal or perimenopausal women, there were 5 who developed AD, 4 who were perimenopausal at baseline and 1 who was still menstruating at baseline. The mean age of the women who were premenopausal or perimenopausal was 42.9 (± 4.0) years; many of these women carrying high-risk alleles may have been too young to develop AD, attenuating the estimate of risk in the total group.
Polymorphisms or haplotypes in ESR2 have been associated with an increased risk for a number of estrogen-related disorders, including osteoporosis [47,48,49,50,51], breast cancer, ovarian cancer [52,53,54,55,56,57,58,59,60] and polycystic ovarian disease . ER-β is found in high concentrations in the hippocampus , and its activation has been linked to synaptic plasticity and hippocampal-dependent cognition [13,62]. Ovariectomized female Esr2–/– knockout mice perform worse than wild-type mice in a spatial learning task and fail to show improvements in learning and memory when treated with estradiol [13,62], suggesting that the effects of estrogen on hippocampal plasticity and memory may be mediated through ER-β . ER-β can couple to rapid signaling events and is required for estrogen-mediated neuroprotection . Thus, variants in ESR2 may influence cognition via a number of different pathways, including modification of hormone levels, changes in gene activity or changes in gene expression. However, specific pathways through which SNP activity modifies receptor function have not yet been identified.
Previous studies of the relationships of polymorphisms in ESR2 to the risk of AD have found a number of different SNPs to be associated with both increased and decreased risk. In 2 studies, SNPs in ESR2 (rs1256065, rs1271573 and rs1256043) were associated with an increased risk for cognitive impairment or AD in women but not in men [29,64], or were associated with an increased risk in men but not in women (rs1255998) . Another study found a cystosine-adenine repeat in ESR2 that was more strongly protective in men than in women , and the Health ABC study found 1 SNP on ESR2 (rs1256030) that was associated with the development of cognitive impairment among both men and women . A diplotype including rs4986938 in the 3′ UTR region of ESR2 has been associated with the risk for AD in both men and women , and rs4986938 has been associated with vascular dementia . Our finding of a 2-fold increase in the risk of developing AD among women carrying rs4986938 is consistent with prior studies [30,31], but we did not see strong associations with rs1256065 or rs1256043, as seen previously [29,33]. We have identified 3 new SNPS of ESR2, rs17766755, rs4365213 and rs12435857, in introns seven (rs17766755) and six (rs4365213 and rs12435857). These SNPs are in high linkage disequilibrium and are associated with a 2-fold increased risk of AD.
Our study points to the role of genetic variants that influence estrogen receptor activity in modifying the risk for AD. Our results support and extend findings from prior studies suggesting that variants in ESR2 modify the risk for AD, both in the general population and in this high-risk group of women with DS. With the exception of rs1255998, all SNPs examined were intronic: rs1255998 is located in exon nine, but does not involve a coding change. The 12 additional SNPs were tested in noncoding (intron) regions and therefore they may not be the critical location of the pathological variants, but rather serve as markers for the critical region. Analysis of additional polymorphisms influencing estrogen biosynthetic pathways and estrogen receptor activity with additional and denser SNP coverage and correlative studies in brain cells will be useful to determine the contribution of estrogen variants to cognitive aging and a risk for AD.
Our work was supported by federal grants AG014673 and HD035897 and by funds provided by New York State through its Office of People With Developmental Disabilities.
Nicole Schupf, PhD
Taub Institute for Research on Alzheimer’s Disease and the Aging Brain
PO Box 16, 630 West 168th Street
New York, NY 10032 (USA)
Tel. +1 212 305 2381, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.